Overview Performance Dividends Fundamentals Peer Group Correlations Pair Trades Institutions Insider Forecasts Options

AZN - AstraZeneca PLC ADR - Stock Price & Dividends

Exchange: USA Stocks • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US0463531089

Cancer, Diabetes, Heart, Vaccines, Respiratory, Cardiovascular, RareDisease

AstraZeneca PLC, a global biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing a wide range of innovative prescription medicines to address complex medical issues.

Their extensive product portfolio includes well-established brands and newer products in several key areas: oncology, cardiovascular, renal, and metabolism. Notable products include Tagrisso, Imfinzi, and Lynparza, which have shown promising results in cancer treatments, as well as Calquence and Enhertu, which target specific types of blood cancer. AstraZeneca has also made significant advancements in cardiovascular health, with products like Brilinta, Lokelma, and Roxadustat addressing conditions such as high blood pressure, atrial fibrillation, and heart failure. Furthermore, their portfolio includes products that help manage conditions such as diabetes and respiratory issues, with brands like Farxiga and Symbicort being popular choices among patients.

In addition to their efforts in these therapeutic areas, AstraZeneca is committed to developing and commercializing innovative products to address the needs of patients affected by rare diseases. Products like Soliris and Ultomiris are part of this initiative, and the company is working on developing more products that address specific needs in the rare disease community. Moreover, the company is committed to contributing to the fight against the ongoing COVID-19 pandemic through their products and partnerships, such as their work with BenevolentAI, a leading company in the field of artificial intelligence.

AstraZeneca distributes its products to primary care and specialty care physicians through various channels, including distributors and local representative offices. This ensures that their products are widely available and can reach the maximum number of patients worldwide. With operations spanning across the United Kingdom, the rest of Europe, the Americas, Asia, Africa, and Australasia, the company is truly global and is well-positioned to serve diverse markets.

AstraZeneca was incorporated in 1992 as Zeneca Group PLC and was rebranded as AstraZeneca PLC in April 1999, after its merger with Astra AB. Since then, the company has grown and evolved to become one of the world's leading biopharmaceutical companies. It is headquartered in Cambridge, in the United Kingdom, and its web URL is https://www.astrazeneca.com.

Drawdown (Underwater) Chart

Overall Trend and Yearly Seasonality

AZN Stock Overview

Market Cap in USD	238,013m
Sector	Healthcare
Industry	Drug Manufacturers - General
GiC SubIndustry	Pharmaceuticals
TER	0.00%
IPO / Inception	1993-05-12

AZN Stock Ratings

Growth 5y	71.9
Fundamental	55.9
Dividend	42.6
Rel. Performance vs Sector	1.04
Analysts	4.38/5
Fair Price Momentum	79.74 USD
Fair Price DCF	49.98 USD

AZN Dividends

Dividend Yield 12m	1.86%
Yield on Cost 5y	3.70%
Dividends CAGR 5y	0.70%
Payout Consistency	96.7%

AZN Growth Ratios

Growth 12m	11.95%
Growth Correlation 12m	39%
Growth Correlation 3m	33%
CAGR 5y	14.77%
CAGR/Mean DD 5y	1.97
Sharpe Ratio 12m	0.34
Alpha vs SP500 12m	-2.15
Beta vs SP500 5y weekly	0.56
ValueRay RSI	40.84
Volatility GJR Garch 1y	21.45%
Price / SMA 50	-0.46%
Price / SMA 200	12.68%
Current Volume	5878.5k
Average Volume 20d	3610.2k

External Links for AZN Stock

News
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle

What is the price of AZN stocks?
As of July 27, 2024, the stock is trading at USD 78.13 with a total of 5,878,519 shares traded.
Over the past week, the price has changed by -0.74%, over one month by -1.20%, over three months by +3.94% and over the past year by +11.37%.

What are the forecast for AZN stock price target?
According to ValueRays Forecast Model, AZN AstraZeneca PLC ADR will be worth about 87.3 in July 2025. The stock is currently trading at 78.13. This means that the stock has a potential upside of +11.71%.

Issuer	Forecast	Upside
Wallstreet Target Price	89.6	14.6
Analysts Target Price	83.7	7.14
ValueRay Target Price	87.3	11.7

AstraZeneca PLC ADR: Its Journey, Core, and Market Standing

History of AstraZeneca

AstraZeneca, a global name in the pharmaceutical and biopharmaceutical industry, was founded through the merger of Astra AB and Zeneca Group PLC in 1999. Astra AB of Sweden and Zeneca Group of the United Kingdom, both having rich histories in healthcare and chemicals, combined their strengths to form a powerhouse. This merger was not just a fusion of two companies but a strategic move to enhance research capabilities, expand product portfolios, and improve global presence in the competitive pharmaceutical market.

Core and Side Businesses

The core business of AstraZeneca revolves around the discovery, development, and commercialization of prescription medicines. The company operates primarily in three main therapeutic areas: Oncology, Cardiovascular, Renal & Metabolism (CVRM), and Respiratory. AstraZeneca's efforts in these areas have led to the development of breakthrough therapies and treatments that have significantly impacted patients' lives worldwide.

Beyond its pharmaceutical ventures, AstraZeneca also invests in biotech startup companies through its venture fund arm. This not only helps the company stay at the forefront of biotechnological advancements but also diversifies its business interests and revenue streams.

Current Market Status

As of the latest update, AstraZeneca PLC ADR (NASDAQ:AZN) continues to be a prominent player in the pharmaceutical industry, with a robust presence in markets across the globe. The company's strategic collaborations, innovative drug pipeline, and a strong focus on research and development have positioned it well for sustainable growth. Investors and market analysts often highlight AstraZeneca's growth potential, especially in emerging markets and through its next-generation therapies.

The COVID-19 pandemic brought significant attention to AstraZeneca due to its development of a vaccine in collaboration with Oxford University. This not only showcased the company's rapid response capabilities in public health emergencies but also its commitment to addressing global health challenges.

In the ever-evolving world of healthcare and pharmaceuticals, AstraZeneca remains a key figure, pushing forward with its mission to deliver life-changing medicines and contribute to the betterment of global health.